HGH Fragment โ€ข Not FDA-Approved

AOD-9604: The “Fat Loss” Fragment: Rodent Results vs. Human Trials

๐Ÿ“„ 5 PubMed citations

Last updated: October 2026

AOD-9604 is a synthetic peptide corresponding to amino acids 177โ€“191 of human growth hormone (plus an added tyrosine), the C-terminal region linked to growth hormone's lipolytic activity. In obese rodents it raised lipolysis markers and reduced weight gain and body fat. In human trials it did not raise IGF-1 or impair glucose tolerance; a 12-week randomized trial reported an average 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo (no dose-response: 10 mg/day lost less), but a larger 24-week trial did not show a significant weight-loss benefit over placebo. Not FDA-approved.

24 wk
Human Trial
(no significant weight loss)
16
Amino Acids
(Tyr + hGH 177โ€“191)
6
Placebo-Controlled
Human Trials
Short answer

AOD-9604 is a synthetic peptide matching amino acids 177โ€“191 of human growth hormone, plus an added tyrosine, studied for fat loss. A 12-week trial reported 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo, but a larger 24-week trial showed no significant weight loss vs placebo. It is not FDA-approved.

Track your vials and inventory on paper

Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

What Is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of the growth hormone sequence plus an added tyrosine (the C-terminal region linked to growth hormone's lipolytic activity), designed to avoid its growth-promoting effects.

๐Ÿ”ฅ
Stimulates Lipolysis

In obese mice and rats, AOD-9604 increased markers of lipolysis (the breakdown of stored fat) and fat oxidation and reduced weight gain. In humans, a 12-week randomized trial reported an average 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo (no dose-response: 10 mg/day lost less), but a larger 24-week trial did not show a significant weight-loss benefit over placebo.

๐Ÿšซ
No IGF-1 Effect

In sponsor-run human trials, AOD-9604 did not raise serum IGF-1 or impair glucose tolerance, unlike full-length HGH. In lab assays it did not bind the growth hormone receptor or drive cell proliferation.

๐Ÿ›‘
Anti-Lipogenic (Design Goal)

AOD-9604 was designed to keep growth hormone's anti-lipogenic signalling: slowing the synthesis and storage of fat (lipogenesis), not the creation of new fat cells. Human data showing a meaningful effect are lacking.

๐Ÿ’‰
Route & Safety

Human trials tested oral and intravenous dosing; subcutaneous injection is what online protocols describe. Sponsor-reported trials found tolerability similar to placebo, but no long-term safety data exist.

What the Research Shows

Animal and human data on AOD-9604: a 12-week human trial reported more weight loss than placebo on 1 mg/day, but the rodent fat-loss signal was not confirmed in a larger 24-week trial.

๐Ÿ“‹ Regulatory Status Research Only (US)

AOD-9604 is not FDA approved and is not approved for any indication by major regulatory agencies. FDA previously placed it in Category 2 of its compounding bulk-substance interim policy (substances that may present significant safety risks, citing possible immunogenicity, peptide-related impurity and API-characterization concerns, and serious adverse events that may be associated with AOD-9604, though causality is not clear); the nominator withdrew it, and FDA now lists it as “nominated but withdrawn.” Human efficacy results are mostly sponsor-reported rather than peer-reviewed.

Lipolysis Stimulation
Raised lipolysis markers in obese mice and rats
Animal data
IGF-1 Independence
No IGF-1 rise or glucose-tolerance impairment in human trials
Human trials
Weight Loss (Animal Studies)
Reduced body weight and body fat in obese rodent models
Demonstrated
Weight Loss (Human Trial)
No significant benefit vs placebo on the primary endpoint (24 weeks, oral)
Not shown
Source ยท Rats
Ng et al., Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Horm Res, 2000 ยท PMID: 11146367
Source ยท Obese mice
Heffernan et al., Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Int J Obes Relat Metab Disord, 2001 ยท PMID: 11673763
Source ยท Obese mice, body fat
Heffernan et al., The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and ฮฒ3-AR knock-out mice
Endocrinology, 2001 ยท PMID: 11713213
Source ยท Human safety, IGF-1, glucose
Stier, Vos & Kenley, Safety and tolerability of the hexadecapeptide AOD9604 in humans (six randomized placebo-controlled trials)
J Endocrinol Metab, 2013;3(1-2):7-15 ยท journal page (not PubMed-indexed)
Source ยท 12-week human trial result
Valentino, Lin & Waldman, Central and peripheral molecular targets for antiobesity pharmacotherapy (review)
Clin Pharmacol Ther, 2010 ยท PMID: 20445536
Source ยท 24-week human trial, dosing, approval status
Dominikowski et al., The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis (review)
Front Endocrinol, 2026 ยท PMID: 42395176
Source ยท FDA compounding status
FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
U.S. Food and Drug Administration, content current as of 04/22/2026 ยท fda.gov

Key Takeaways

What We Know
  • HGH fragment (amino acids 177-191)
  • Raised lipolysis markers and cut weight gain in obese rodents
  • Did not raise IGF-1 or impair glucose tolerance in human trials
  • A 12-week trial reported 2.6 kg vs 0.8 kg loss (1 mg/day, no dose-response); a larger 24-week trial showed no significant weight loss vs placebo
  • Did not bind the GH receptor or drive cell proliferation in lab assays
What We Don't Know
  • Limited peer-reviewed human efficacy data (mostly sponsor-reported)
  • Not FDA approved in US
  • Optimal dosing protocols not established
  • Long-term safety unknown

Verified Research Source

Research compounds from Swiss Chems, our affiliate supplier.

Browse Swiss Chems โ†’
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).

๐Ÿ’ช Follistatin Guide ๐Ÿ“– Peptide Encyclopedia ๐Ÿงฎ Dosing Calculator
Trusted Vendor

Research-Grade Peptides

Research compounds from Swiss Chems, our affiliate supplier; vendor-published COAs for selected products.

Browse Swiss Chems โ†’
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

๐Ÿ“š

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.


Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Important Disclaimer

This page is for educational purposes only. AOD-9604 is not FDA approved. Always consult a healthcare provider.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.